BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. Presented additional positive data from the ongoing Phase 1 trials of CUE-101 in first line (1L) human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in combination with ...

✓ Generation of a Therapeutic Index for IL-2 > Selective targeting of IL-2 to tumor-specific T cells ✓ Clinical Validation and PoC (>100 Patients Treated) > Monotherapy activity in late-stage cancer patients > Potential doubling of ORR and mPFS in combination with CPI ์ Favorable Tolerability Profile ✓ Strong Metrics of Manufacturability Flexible Platform with Potential Regulatory Advantages The structural design of our IL-2 based CUE-100 series antibody-based molecules enables modularity of the various com ...

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following ...

Financing Activities During the nine months ended September 30, 2023 and 2022, we generated cash from financing activities of $7,078,000 and $26,256,000, respectively, a decrease of $19,178,000. Cash from financing activities during the nine months ended September 30, 2023 consisted of cash proceeds from the sale of common stock pursuant to the October 2021 ATM Agreement of $7,605,000 net of sales agent commissions and fees, and cash proceeds from the exercise of stock options of $473,000. Cash from financi ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-----------------------|------------|---------------------| | | | June 30, 2023 \n(in | thousands) | December 31, 2022 | | Laboratory equipment | $ | 5,205 | $ | 5,246 | | Furniture and fixtures | | 81 | | 81 | | Computer and office equipment | | 296 | | 296 | | Leasehold improvements | | 118 | | 118 | | | | 5,699 | | 5,741 | | Less accumulated depreciation | | (4,507 | ) | (4,242 ) | | Net property and equipment | $ | 1,192 | $ ...

Principal Commitments As a smaller reporting company, we are not required to provide the information required by this Item 3. Inherent Limitations on Effectiveness of Controls PART II. OTHER INFORMATION We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen ...

WASHINGTON, D.C. 20549 Cue Biopharma, Inc. 02135 (ZipCode) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐ No ☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, as of the last business day of the registrant's most recently completed second fiscal quarter, was approximately $82.1 million (based on the closing price of the registrant's common stock on June 30, 2022 of $2.49 per share). ...